Surveillance After COVID-19 mRNA Vaccination

JAMA

EMBARGOED FOR RELEASE: 11 A.M. (ET), FRIDAY, SEPTEMBER 3, 2021

Media advisory: The full study and editorial are linked to this news release.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2021.15072?guestAccessKey=80d0f334-1f66-421b-b740-a5bba31ac7a6&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=090321

 

What The Study Did: In this interim analysis of surveillance data from 6.2 million people who received 11.8 million doses of an mRNA vaccine, event rates for 23 serious health outcomes weren’t significantly higher for individuals one to 21 days after vaccination compared with similar individuals at 22 to 42 days after vaccination.

Authors: Nicola P. Klein, M.D., Ph.D., of Kaiser Permanente Northern California in Oakland, is the corresponding author.

 

(doi:10.1001/jama.2021.15072)

Editor’s Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.